HBM Holdings Limited announces that (i) Mr. Junfeng Wang ("Mr. Wang") has tendered his resignation as non-executive Director and (ii) Mr. Yu Min Qiu ("Mr. Qiu") has tendered his resignation as non-executive Director and member of the Audit Committee, with effect from 13 July 2023, due to their respective other business engagements which require more of their time and dedication. The Board announce that Dr. Albert R. Collinson (" Dr. Collinson ") has been appointed as an independent non-executive Director with effect from 13 July 2023. Dr. Collinson, aged 65, has over 30 years of experience in the pharmaceutical and biotechnology industries. Dr. Collinson has been the president and chief executive officer at Theracos Inc. since July 2009, a pharmaceutical research and development company focusing on mid- to late- stage assets for the treatment of human diseases including type-2 diabetes. Prior to joining the Group, Dr. Collinson founded and served as president and chief executive officer of Opsonic Therapeutics from 2009 to June 2014, a privately held biotechnology company engaged in the development of the next generation of antibody therapeutics. Dr. Collinson also served as the chief business officer of Rib-X Pharmaceuticals from 2004 to 2009, the senior vice president of business development at Phylos Inc. from 2000 to 2004, and the vice president of global research & development licensing
at BASF Pharma from 1998 to 2000. Dr. Collinson began his career as a scientist at ImmunoGen Inc. Dr. Collinson received his Ph.D. in Biochemistry from Brandeis University in 1987 and his bachelor's degree in science in Biology (General) from the University of Rhode Island in 1980. Dr. Collinson was a post-doctoral fellow at the Dana Farber Cancer Institute and Harvard Medical School. The Board hereby announces that following the resignation of Mr. Qiu, Ms. Weiwei Chen, a non-executive Director, has been appointed as a member of the Audit Committee with effect from 13 July 2023.